Piramal Pharma Ltd. Fundamental & Technical Research, Share Price Today

NSE : PPLPHARMA
NIFTY : Nifty 500

About Company

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across several global facilities and a global distribution network in hundreds of countries. It includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies.

Market Cap. ₹27,979 Cr.

52 Week - High/Low ₹308/136

P/E Ratio 40.66

P/B Ratio 4.17

Enterprise Value ₹28,597 Cr.

ROE % 6.55

RSI Value 76.36

EMA 50 218.28

EMA 200 212.06

Net Profit 391 Cr.

Net Profit 3year growth -31.55 Cr.

Net Profit 3 year (back) 572 Cr.

Debt to Equity 0.17 %

EPS Growth TTM 5.74 %

Current Ratio 1.46 %

100 Day SMA 227 Rs.

200 Day SMA 222 Rs.

21 Day SMA 220 Rs.

50 Day SMA 212 Rs.

Book Value 51 Rs.

EV/EBITDA Ratio 23

QoQ EPS Growth -43 %

QoQ Operating Profit Growth -13 %

QoQ Sales Growth -3 %

Sales Latest Quarter 1,248 Cr.

YoY Sales Growth 22 %

Market Cap. ₹27,979 Cr.

52 Week - High/Low ₹308/136

P/E Ratio 703.47

P/B Ratio 3.54

Enterprise Value ₹30,425 Cr.

ROE % 0.24

RSI Value 76.36

EMA 50 218.28

EMA 200 212.06

Net Profit 18 Cr.

Net Profit 3year growth 29.72 Cr.

Net Profit 3 year (back) 835 Cr.

Debt to Equity 0.58 %

EPS Growth TTM -207.14 %

Current Ratio 1.25 %

100 Day SMA 227 Rs.

200 Day SMA 222 Rs.

21 Day SMA 220 Rs.

50 Day SMA 212 Rs.

Book Value 60 Rs.

EV/EBITDA Ratio 19

QoQ EPS Growth -84 %

QoQ Operating Profit Growth -1 %

QoQ Sales Growth -2 %

Sales Latest Quarter 2,204 Cr.

YoY Sales Growth 13 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages